CHERYL CONFER: Open Payments
NPI 1912651548 · DECATUR, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,064 in 110 payments from 16 companies in 2025. Trend: 2023 $23 · 2024 $1,002 · 2025 $2,064
Food & beverage: $2,064
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $371 |
| Otsuka America Pharmaceutical, Inc. | 23 | $368 |
| Alkermes, Inc. | 12 | $294 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $269 |
| Corium, LLC | 11 | $257 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $140 |
| Teva Pharmaceuticals USA, Inc. | 5 | $90 |
| Almatica Pharma LLC | 3 | $64 |
| Janssen Pharmaceuticals, Inc | 3 | $51 |
| Neurocrine BioSciences, Inc. | 2 | $48 |
Products named: VRAYLAR, REXULTI, ARISTADA, CAPLYTA, Azstarys, TRINTELLIX, LOREEV XR, AUSTEDO XR.
Industry payments across AL — which companies pay providers there.
